Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Galectin Therapeutics Inc. (NASDAQ: GALT) will participate in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Joel Lewis and CMO Dr. Pol F. Boudes will present for the company. The presentation will be available as a webcast at 7:00 a.m. ET on January 10, 2022, and can be accessed on the company's website, with a replay available for 90 days.

Galectin focuses on developing therapies for chronic liver disease and cancer, with its lead drug, belapectin, targeting the galectin-3 protein and receiving Fast Track designation from the FDA for NASH-related fibrosis.

NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022. Mr. Joel Lewis, President and Chief Executive Officer, and Dr. Pol F. Boudes, Chief Medical Officer, will be presenting on behalf of the Company.

A webcast of this presentation will be available on the “Investor Relations” section under “Events and Presentations” of the Company’s website, https://investor.galectintherapeutics.com, at 7:00 a.m. ET on January 10, 2022. A replay will be accessible on Galectin’s website for 90 days following the event.

About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of combination immunotherapy for advanced melanoma and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.

Company Contact:

Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor GR-MD-02.

FAQ

When will Galectin Therapeutics present at the H.C. Wainwright BioConnect Conference?

Galectin Therapeutics will present at the H.C. Wainwright BioConnect Conference on January 10, 2022, at 7:00 a.m. ET.

Who will represent Galectin Therapeutics at the conference?

CEO Joel Lewis and CMO Dr. Pol F. Boudes will represent Galectin Therapeutics at the conference.

How can I access the presentation by Galectin Therapeutics at the conference?

The presentation can be accessed as a webcast on Galectin Therapeutics' website under the 'Investor Relations' section.

What is the focus of Galectin Therapeutics?

Galectin Therapeutics focuses on developing therapies for chronic liver disease and cancer, particularly targeting galectin proteins.

What is belapectin and its significance?

Belapectin is Galectin's lead drug targeting the galectin-3 protein, which has received Fast Track designation from the FDA for treating NASH-related fibrosis.